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The immune system provides an attractive option for
use in cancer therapy. Our increasing understanding
of the molecular events important in the generation
of an effective immune response presents us with the
opportunity to manipulate key genes to boost the im-
mune response against cancer. Genetic modification
is being employed to enhance a range of immune pro-
cesses including antigen presentation, activation of
specific T cells, and localization of immune effectors
to tumors. In this review, we describe how many di-
verse cell types, including dendritic cells, T cells, and
tumor cells, are being modified with a variety of
genes, including those encoding antigens, cytokines,
and chemokines, in order to enhance tumor immunity.
Introduction
The immune system is a promising tool for use in the
therapy of cancer due to the range of effector mecha-
nisms possessed by a diversity of immune cell types
and its ability to exert effects with exquisite specificity.
A variety of tumor-associated antigens (TAA) have been
identified that singly, or in combination, can be used
to discriminate between normal and malignant tissue.
Successes with immunotherapeutic approaches, such
as vaccines, cytokine administration, and adoptive cell
transfer, have demonstrated that the immune system
can be manipulated to produce dramatic antitumor re-
sponses against some malignancies, and these suc-
cesses are driving intense interest in the field (Rosen-
berg, 2001). However, complete durable responses are
rare, and immunotherapies frequently fail to prevent tu-
mor growth (Rosenberg et al., 2004).
In asking ourselves why success with current immu-
notherapies is so limited, it is instructive to consider
the known requirements for an effective immune re-
sponse to infectious disease. The immune response is
a multistep process, requiring antigen presentation, ac-
tivation and expansion of specific T cells, and localiza-
tion of immune effectors to the site of challenge (Figure
1). This process involves a progression of molecular in-
teractions between various cell types resulting from the
coordinated expression of specific genes. Immune pro-
cesses can therefore be viewed as a developing ge-
netic program, where initiation of the response begins
a genetic cascade whose individual constituents are
essential contributors to the outcome of immunity. In
cancer, however, the immune process can fail at several*Correspondence: michael.kershaw@petermac.orgcrucial stages. The identification of key failure points
in this genetic program provides us with intervention
strategies to correct deficiencies in the response
against cancer. The following provides a review of ge-
netic intervention strategies to overcome existing
limitations of immune defenses at five crucial stages of
the adaptive immune response (Figure 1) and discusses
how these might be integrated to develop improved
therapies for cancer.
Stage 1: Initiation of Antitumor Immune Responses
The initiation of an immune response is a complex
series of events involving danger signals, secretion of
cytokines and inflammatory mediators, and the partici-
pation of antigen-presenting cells (APCs) that take up
antigen, mature, and migrate to lymph nodes where
they present antigen to T cells (see stage 1, Figure 1).
Conceivably, tumors may not be considered as a threat
to self per se, and any of these required steps might be
deficient or suboptimal. A range of genetic strategies
seeks to enhance one or more of these requirements in
order to achieve an effective immune response against
tumors.
Some of the earliest genetic vaccine studies in mice
utilized a number of alternate vector forms including
plasmid DNA or recombinant viruses that encoded
model antigens such as β-galactosidase. Vaccination
with these vectors could result in tumor growth inhibi-
tion in mice, and the therapeutic effect could be en-
hanced by providing cytokines such as IL-2 either ex-
ogenously or incorporated into the same vector (Irvine
et al., 1996). Although encouraging, these first suc-
cesses were limited to inhibition of small tumors ex-
pressing foreign antigens. In attempts to broaden the
application and enhance the antitumor effect of genetic
vaccines, investigators have modified enriched popula-
tions of dendritic cells in vitro using various vectors,
which are then used as cellular vaccines. Ex vivo modi-
fication of both human and mouse DCs with genes en-
coding tumor antigens, including self-antigens, has
been shown to effectively stimulate T cell responses
in vitro and in various murine models, with induction
of long-term immunity against tumors expressing the
corresponding antigens. However, effectiveness was
generally restricted to early stage disease or protection
against tumor challenge (Ribas et al., 2002).
An alternative to DNA-encoded antigens is the use of
RNA for the modification of DCs. Early studies utilizing
mRNA encoding model tumor antigens in DC vaccine
strategies served as proof of principle that antigen-spe-
cific T cells could be generated and protection con-
ferred against tumors in this way. This work quickly led
to the use of tumor-derived polyA RNA to induce immu-
nity against poorly immunogenic tumors (Boczkowski
et al., 1996). An advantage of this type of approach is
that tumor RNA or cDNA may provide an unlimited
source of potential antigens without the need for prior
antigen identification or characterization. However, this
latter approach may be limited to highly expressed anti-
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oFigure 1. Five Key Stages in a Successful Immune Response
hThis schematic represents cells of an infected tissue (purple), to-
gether with a lymph node draining this tissue (yellow) and blood 2
vessels supplying the tissue (pink). Initiation of the immune re- v
sponse is represented as stage 1, where an antigen-loaded den- w
dritic cell (DC, in green) is shown migrating to the regional lymph a
node after acquiring antigen and receiving “danger” signals, indi-
cating a potential threat to the body. It then interacts with a T cell
t(red) that specifically recognizes the antigen presented by the DC.
This is shown as stage 2. Stage 3 signifies clonal expansion and i
differentiation of the relevant T cell populations within the regional m
lymph node, leading to stage 4, where a proportion of these cells c
migrates and localizes at the affected body site. Stage 5 denotes m
the exertion of effector functions by T cells within the affected tis-
ssue. This may constitute direct cytolytic effects and/or the pro-
hduction of cytokines, followed by recruitment and activation of fur-
ather leukocytes. If all these steps proceed successfully, the
resulting immune amplification will lead to clearance of the infec- m
tion and resolution of the potential threat. 1
i
mgens, and the low stability of RNA may reduce the ap-
1plication of these strategies.
tReplicon-based RNA vaccines offer an interesting al-
s
ternative to normal RNA that takes advantage of the
c
replicase of alphaviruses that can generate large
c
amounts of RNA. Replication of RNA can lead to very
high levels of gene expression. Replicon vectors can o
be produced in several forms including RNA and DNA s
that can be delivered in various ways including gene H
gun or as virus particles. Replicon-based vaccines m
have been demonstrated to induce antitumor immune o
responses and impact on tumor growth in mice (Gilboa l
and Vieweg, 2004).
Based on the above results utilizing antigen-engi- s
neered DCs in vitro and in mouse studies, vaccination i
with autologous gene-modified DCs has proceeded to t
phase I and II clinical trials achieving some immunolog- i
ical responses in patients with renal (Su et al., 2003), t
colon (Morse et al., 2003) or other cancers (Pecher et r
al., 2002), with evidence of tumor-specific T cell expan- a
sion. Additionally, there was no evidence of toxicity or e
autoimmunity in these trials, demonstrating the safety m
of this therapeutic approach. However, high rates of a
disease progression were observed, requiring most pa- 2
tients to undergo alternate therapies. Clearly, the com- w
plex nature of an immune response is not easily repli- g
cated by simply providing DCs with antigen. Many t
other factors are important including the maturation m
state of DCs, whereby increases in major histocompati- e
bility complex (MHC) and costimulatory molecule ex- 2
pression render DCs better able to stimulate T cells.One tactic to trigger local DCs to mature, to secrete
nflammatory mediators, and to present tumor antigen
o lymphocytes is to introduce CD40 ligand (CD40L), a
otent dendritic cell activation molecule, into the tumor
icroenvironment by gene transfer. Adenoviral trans-
uction of CD40L into tumor cells has been demon-
trated to promote the maturation of dendritic cells
n vitro, as measured by an increase in the number of
D83+ and MHC class II+ DCs and increased secretion
f IL-12. Intratumoral injection of this CD40L-express-
ng vector into tumor-bearing mice induced a 200-fold
ncrease in IL-12 mRNA and a corresponding reduction
n the DC-inhibitory cytokine IL-10 in the tumor area of
ice (Buelens et al., 1997). This therapy was capable
f causing regression of small tumors in mice and in-
ibiting the progression of larger tumors (Loskog et al.,
004). These findings are supported by several other in
itro and in vivo studies (Kikuchi and Crystal, 1999), as
ell as in a clinical trial of leukemia patients (Wierda et
l., 2000).
Another factor important in stimulation and matura-
ion of innate immune cells is the presence of cytokines
n the tumor micromilieu, which can affect innate im-
une cell activity. One of the most extensively studied
ytokine gene-modification approaches has been to
odify tumor cells to express GM-CSF, which has been
hown in multiple murine models to significantly en-
ance antitumor responses through improved tumor
ntigen presentation by recruited dendritic cells and
acrophages (Dranoff et al., 1993; Levitsky et al.,
996). This immunization strategy has also been tested
n clinical trials of patients with renal cell carcinoma (Si-
ons et al., 1997), metastatic melanoma (Soiffer et al.,
998), and pancreatic cancer (Jaffee et al., 2001), with
he majority of patients biopsied demonstrating exten-
ive inflammatory infiltrate within the tumors, often in
onjunction with increased tumor-specific T lympho-
yte activity and, in some cases, tumor regression.
Flt3 ligand is another cytokine important in the devel-
pment of DCs, and genetically modified tumor cells
ecreting Flt3 liter have reduced tumorigenicity in mice.
owever, direct comparison of GM-CSF- and Flt3-L-
odified tumor cells has revealed the superior activity
f GM-CSF, perhaps due to the induction of higher
evels of B7.1 and CD1d on DCs (Mach et al., 2000).
The process of inflammation is central to creating a
ense of danger that aids recruitment of leukocytes and
nitiates efficient antigen presentation. Cytokine gene
ransfer into tumors has been employed to address this
ssue. For example, tumors secreting the proinflamma-
ory cytokine IL-1β have been demonstrated to have
educed tumorigenicity and to have effect as a vaccine
gainst established tumors (Bjorkdahl et al., 2000). Ad-
novirus-mediated gene transfer of the IL-1 family
ember IL-1H4 into established murine sarcoma has
lso succeeded in inhibiting tumor growth (Gao et al.,
003b). The importance of T cells in antitumor activity
as also demonstrated in these studies. However, the
enetic provision of IL-1β is not always associated with
umor inhibition. Indeed, depending on the tumor
odel, IL-1β can increase inflammation and angiogen-
sis, leading to enhanced tumor growth (Saijo et al.,
002).
Other proinflammatory cytokines have also been
Review
405used in attempts to enhance antitumor responses.
Genes encoding IL-12 or IL-18 have been demon-
strated to promote tumor inhibition (Nishioka et al.,
1999; Tatsumi et al., 2002). Utilization of these cyto-
kines has the added benefit of promoting a Th1-type
immune response that is generally more effective than
a Th2 response at inhibiting tumor growth. A phase I
trial involving injection of IL-12-transduced fibroblast
cells into tumor sites of late-stage cancer patients has
also been completed, with tumor necrosis and transient
but clear reductions in tumor size observed in approxi-
mately half of patients (Kang et al., 2001).
An important consideration in the design of tumor
gene-modification strategies is the mode of vector de-
livery. Intratumoral injection of vectors can result in
safe, effective, local production of immunomodulators
(Sung et al., 2002) but is impractical in many clinical
situations. Targeted vectors, on the other hand, may
provide tumor-specific delivery of genes with viral or
non-viral vectors (Wickham, 2003). Enhanced vector
targeting to tumors can be mediated through incorpo-
ration of appropriate ligands or antibodies into viral
coats.
As these strategies to stimulate host antitumor im-
munity developed, researchers investigated engineer-
ing cells with more than one immunostimulatory gene
in further attempts to induce more robust antitumor re-
sponses. For example, intratumoral injection of DCs
engineered to secrete both IL-12 and IL-18—two cyto-
kines known to act synergistically to drive Th1-type
(cellular) immune responses—was found to promote tu-
mor regression in murine sarcoma models through acti-
vation of CD4+ and CD8+ T cells that secreted high
levels of IFN-γ. These IL-12/IL-18 cytokine gene-engi-
neered DCs expressed higher levels of MHC and co-
stimulatory molecules than nontransduced DCs or
those engineered with either cytokine alone (Tatsumi et
al., 2003). Additionally, murine studies have investi-
gated the efficacy of supplying other cytokine genes
such as TNF-α, IL-7, and IL-12, either alone or in com-
bination with other genes, such as costimulatory or TAA
genes. These studies in mice have boasted marked re-
duction in tumor burden, with extensive lymphocyte in-
filtration into the tumors, as well as enhanced survival
(Chen et al., 2002; Narvaiza et al., 2000; Sharma et al.,
2003; Tatsumi et al., 2003).
Transduction of more than one gene has proven su-
perior to a single gene by targeting multiple facets of
the initiation of an immune response. These results
support the potential of combined gene transfer ap-
proaches to enhance multiple DC effector functions
and, consequently, accelerate immune-mediated rejec-
tion of tumors. Furthermore, the localized expression of
these genes more closely resembles the physiological
setting and lessens toxicity concerns associated with
systemic administration of DC maturation agents, such
as cytokines or microbial products.
The issue of DC persistence has also received atten-
tion in efforts to generate more effective vaccines. In-
vestigators have gene-modified mouse hematopoietic
stem cells with a model tumor antigen and have dem-
onstrated transgene expression in DCs in recipients of
gene-modified stem cells (Cui et al., 2003). These gene-
modified stem cells, in combination with antigen-spe-cific T cells, soluble Flt3 ligand, and anti-CD40, were
demonstrated to inhibit tumor growth. In addition,
adoptive transfer of gene-modified stem cells was more
effective than transfer of gene-modified DCs. Prolonged
production of stem cell-derived antigen-expressing DCs
with improved lymphoid localizing ability may be poten-
tial reasons for antitumor activity superior to that of
transferred differentiated DCs. Although technically
more challenging at present than manipulating DCs,
this stem cell approach could find application in the
clinic after optimization and further validation.
Other methods to increase the survival of DCs in-
clude modification with genes encoding antiapoptotic
molecules. Cotransfer of genes encoding a model tu-
mor antigen and either of several apoptosis inhibitors
was demonstrated to prolong the survival of DCs and
enhance the generation of antigen-specific T cells
in vivo (Kim et al., 2003). Using a gene gun to deliver
DNA directly into mouse skin, the authors observed im-
proved protection from tumors in mice receiving DNA
encoding both antigen and antiapoptotic molecules. In-
vestigations are also underway to improve DC lifespan
by reducing their sensitivity to tumor-derived inhibition.
Transduction of DCs with antiapoptotic molecules in-
cluding FLIP, XIAP/hILP, dominant-negative procas-
pase-9, and HSP70 can confer resistance to mela-
noma-induced apoptosis (Balkir et al., 2004).
Some limitations in the use of transduced DCs exist,
however, such as the availability and generation of
large numbers of these cells and the determination of
optimal DC preparation and delivery route. Addressing
the issue of response initiation can have dramatic ef-
fects by itself in some mouse tumor models, but
attempts to extend these studies to the clinic have met
with limited success. Clearly, there are limitations to
supplying antigen or inflammatory signals alone. Per-
haps paramount in these limitations is that this ap-
proach relies on stimulating the existing immune reper-
toire of the patient, which may often be deficient or
suppressed due to tolerance induction by the tumor.
Even with the best antigen presentation, an adaptive
immune response cannot proceed if specific T cells
are lacking.
Stage 2: The Requirement for Specific T Cells
The second crucial requirement in the generation of an
effective immune response involves the existence of
antigen-specific T cells with which DCs can interact
(Figure 1, stage 2). Although tumor-reactive T cells have
been detected in some cancer patients, these are re-
stricted to a limited proportion of malignancies. In the
majority of cases patients have become tolerant to their
tumors, and tumor-specific T cells have either been de-
leted, are unresponsive to tumors, react only with non-
physiological targets such as peptide-pulsed APC, or
are not present in large enough numbers to eliminate
tumors.
This high level of tolerance in some patients may
pose a significant barrier to therapeutic vaccination.
One avenue to increase the number of T cells that can
respond to tumors is to genetically engineer T cells of
a cancer patient to provide the T cells with anti-tumor
specificity. One way of achieving this is by gene-modi-
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TCR α and β chains of desired specificity. Adoptive k
transfer of these gene-modified T cells has been found
to confer antitumor reactivity in vitro and in animal b
models (Chamoto et al., 2004; Clay et al., 1999; Stanis- b
lawski et al., 2001). d
Another interesting strategy to provide tumor- t
reactive T cells for prolonged periods involves introduc- f
tion of genes encoding TCR α and β chains into m
hematopoietic precursor cells. T cells derived from pre- d
cursor cells in vivo were demonstrated to become acti-
vated in vivo after immunization and to proliferate and S
secrete cytokines in response to antigen in vitro (Yang o
et al., 2002). Tumor-reactive T cells generated in this A
manner may have a more suitable in vivo phenotype c
than those generated in vitro, which may lead to better e
trafficking and activity in vivo. In addition, their contin- t
ued production from precursors may provide a more s
prolonged assault on tumors and perhaps protection c
from relapse. Suitable TCR may be derived from rare s
responding patients or from transgenic mice immu-
nized with tumor antigen (Stanislawski et al., 2001). a
However, there are drawbacks to the clinical applica- a
tion of this approach, including the large number of tu- o
mor antigen-specific TCR genes that would need to be c
generated to cater for HLA types of every cancer pa- u
tient. In addition, TCRs predominantly recognize only w
protein antigens, excluding a multitude of carbohydrate e
and glycolipid tumor antigens. m
An alternative to using TCR genes to redirect T cells i
is to use the specificity of antibodies against TAA. An r
extensive selection of TAAs has been identified, and m
a range of specific monoclonal antibodies is available, k
which have higher affinities and broader recognition
than TCRs. These can be engineered to behave as o
TCRs by constructing genes encoding chimeric antigen
2
receptors (CARs). CARs link antigen recognition with T
c
cell activation via fusion of the antigen binding domains
t
of a monoclonal antibody with the intracellular signal-
wing domains of molecules of the TCR complex in a sin-
egle integral membrane protein. Genetic engineering to
Tproduce CAR-modified T cells provides an attractive
bmeans of generating large numbers of tumor-specific
weffector cells for adoptive immunotherapy.
oMouse monoclonal antibodies specific for a wide
grange of tumor antigens are readily produced, and T
ecells expressing any of a diverse range of CARs recog-
onizing different tumor antigens can now potentially be
nused to treat multiple types of malignancies (Sadelain
met al., 2003). This approach can be used to endow tu-
mor specificity on both CD4+ and CD8+ T cells, and
aefficiently bypasses some tumor escape mechanisms,
tsuch as MHC downregulation, by recognizing tumor
Bantigens in a non-MHC-restricted manner. Additionally,
ma single gene construct encoding a particular CAR can
tbe used for multiple patients whose tumors bear com-
smon antigens. T cell modification with these genes has
vresulted in highly specific antigen recognition, cytokine
ssecretion, and killing in vitro, and also in retarded tumor
wgrowth in intraperitoneal and subcutaneous murine
models (Sadelain et al., 2003). In addition to these
apromising studies, success with genetically modified
mCTL has led to initiation of phase I clinical trials for re-
lapsed B cell lymphoma (Wang et al., 2004), neuro- tlastoma (Rossig et al., 2002), and ovarian cancer (Par-
er et al., 2000).
Despite the recognition and killing of tumors achieved
y CARs against a range of malignancies, success has
een limited to murine models of early disease or
isseminated tumors. Treatment of established, solid
umors poses a greater challenge, most likely due to
ailure of T cells to expand, localize at tumor sites, and
aintain their function in vivo, issues that are ad-
ressed in the following text.
tage 3: Expansion and Differentiation
f Tumor-Specific Lymphocytes
fter successful interaction with APCs, activated T
ells undergo clonal expansion and differentiation into
ffector and memory cell populations. The majority of
hese activated T cells will then leave the lymphoid tis-
ue and enter the circulation (see Figure 1, stage 3). T
ell proliferation and expansion to high numbers repre-
ents a key determinant of in vivo efficacy.
Although earlier designs of CAR genes could endow
ctivated T cells with effector function, they were not
ble to induce proliferation in response to antigen. To
vercome this limitation, more recent designs of CAR
ombine antigen recognition with simultaneous costim-
lation by incorporation of signaling domains from the
ell-characterized costimulatory molecule CD28 (Maher
t al., 2002) and, more recently, other costimulatory
olecules such as OX-40 (CD134) and 4-1BB (CD137)
nto the CAR (Finney et al., 2004). This results in supe-
ior signaling capacity, when compared with TCR do-
ains alone, with increased capacity to secrete cyto-
ines and to induce T cell proliferation in vitro.
Importantly, this approach can also achieve inhibition
f tumor growth and metastases in vivo (Haynes et al.,
002b). Complete tumor regression was reported when
himeric receptor-modified T lymphocytes, recognizing
he human breast cancer-associated antigen erbB2,
ere injected directly into the subcutaneous erbB2-
xpressing tumors of mice (Altenschmidt et al., 1997).
umor growth retardation and prolonged survival has
een demonstrated by Pinthus et al. in a similar model,
here mice were treated with CAR-modified T cells rec-
gnizing erbB2 (Pinthus et al., 2003). Inhibition of tumor
rowth has also been achieved for tumors expressing
rbB2 and carcinoembryonic antigen (CEA), in a variety
f tumor types, in both subcutaneous and intraperito-
eal murine models after systemic injection of gene-
odified T cells (Haynes et al., 2002a, 2002b).
Given the importance of costimulation in the optimal
ctivation and expansion of T cells, genetic modifica-
ion of tumors with costimulatory molecules such as
7-1 (CD80) and B7-2 (CD86) has been investigated in
urine models. These studies have indicated that
ransfection of CD80 and CD86 into tumor cells and
ubsequent inoculation into mice can induce T cell acti-
ation and cytokine secretion, promote tumor regres-
ion, and protect mice against subsequent challenge
ith parental tumors (Townsend and Allison, 1993).
Costimulatory molecules combined with antigen can
lso be supplied in recombinant viral vectors and im-
unization with these can lead to prolonged survival of
umor-bearing mice (Chamberlain et al., 1996). Interest-
Review
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to possess greater immunostimulatory capacity than
CD86. Further enhancement of antitumor activity has
also been observed in mice receiving vaccination with
viral vectors encoding multiple costimulatory mole-
cules or costimulatory molecules combined with cyto-
kine genes (Carroll et al., 1998).
Encouraged by these and other studies, a clinical trial
of metastatic melanoma patients was initiated in which
a vaccinia vector encoding multiple tumor epitopes, to-
gether with CD80 and CD86 costimulatory genes, was
administered to patients in combination with soluble
melanoma peptides and systemic GM-CSF. Specific
CTL precursor frequencies were shown to briefly in-
crease after injection (Zajac et al., 2003), and regression
of individual metastases was reported in 3 of 18 pa-
tients, with no major clinical toxicity reported. Further
optimization of combination strategies such as this
may lead to enhanced tumor regression.
Additional costimulatory molecules, such as TNF-
family members OX40 ligand and 4-1BB ligand, have
also been reported to have antitumor effects in mice
when introduced into tumor cells by viral vector. En-
gagement of these molecules upon T cell activation has
been shown to increase CD4+ and CD8+ T cell prolifera-
tion and cytokine production and long-term persis-
tence. Strong CTL responses leading to significant sup-
pression of tumor growth and survival advantages were
demonstrated in mice treated intratumorally with viral
vectors containing these genes (Shuford et al., 1997;
Andarini et al., 2004).
Antitumor effects were further enhanced when two
costimulatory molecules were coexpressed in a poorly
immunogenic mouse sarcoma model. Subcutaneous
injection of 4-1BB ligand/CD80-transfected tumors en-
hanced the induction of effector CTL and tumor rejec-
tion, although neither 4-1BBL nor CD80 single transfec-
tants were effective in this model (Melero et al., 1998).
In a similar study, ligands for 4-1BB and CD28 were
transfected into artificial antigen-presenting cells and
found to induce activation, rapid expansion, and in-
creased survival of antigen-specific CD8+ T cells in vitro
(Maus et al., 2002). These studies suggest a synergistic
effect between these costimulatory pathways.
In addition to the modification of T cells and tumors,
DCs can be modified to express both tumor antigens
and costimulatory molecules leading to antitumor ef-
fector and memory CTL responses. The use of DC co-
stimulatory molecules RANK (receptor activator of NF-
κB) and CD40 and/or their T cell-expressed ligands
RANKL and CD40L were investigated by immunization
of mice with DCs expressing a combination of these
molecules (Wiethe et al., 2003). Significantly elevated
numbers of antigen-specific, IFN-γ-secreting effector
and memory T cells were induced in immunized mice
in comparison to nonimmunized mice or mice receiving
DCs transduced with a control vector. Augmentation of
CTL responses was correlated with upregulation of
CD80 and CD86 expression in DCs transduced with
costimulatory molecules, suggesting enhanced antitu-
mor T cell activation and survival may also be achieved
with this type of immunization (Wiethe et al., 2003). An-
other useful combination is the dual use of cytokine
and costimulatory gene transfer, which has been foundto synergistically augment tumor regression in mouse
models in comparison to tumors transduced with single
genes (Putzer et al., 1997). These results have impor-
tant implications for improved tumor antigen-express-
ing vaccines and again emphasize the improved suc-
cess of targeting multiple aspects of the immune
response to achieve antitumor immunity.
Genes encoding cytokines can also be used to en-
hance T cell expansion and survival. Toward this aim,
genes encoding the T cell growth factors IL-2 or IL-7 have
been utilized to transduce tumor cells, thereby provid-
ing a constitutive source of cytokine at the tumor site.
Growth inhibition of tumors has been observed after
expression of IL-2 or IL-7 (Bowman et al., 1998; Hock
et al., 1993).
At present, no immune strategies can enable the im-
mune system to respond against cancer to the same
degree as it responds against infectious agents. Com-
mon infectious agents such as viruses or bacteria are
known to be potent immunogens and to stimulate high-
level proliferation of antigen-specific effector and mem-
ory cell populations in vivo. The immune response
against a virus can lead to enormous expansion of
virus-specific T cells, achieving over 25% of total circu-
lating T cells and long-lasting immunity, providing pro-
tection against subsequent challenges. This is in stark
contrast to the poor immunostimulatory capacity of tu-
mors, where T cell expansion, even against the more
immunogenic malignancies such as melanoma, rarely
exceeds 4% and is more often less than 1%.
In continued efforts to improve the activation, expan-
sion and persistence of specific T cells in tumor immu-
notherapy, researchers have sought to combine the
potential for high-level activation and expansion, exhib-
ited in response to powerful immunogens, with the abil-
ity to react to tumors by creating T cells with two speci-
ficities. In this approach, T cell populations possessing
a highly immunogenic endogenous specificity, such as
viral or bacterial specificity, are genetically modified to
express CARs with antitumor reactivity. This dual-spe-
cific application of gene therapy aims to efficiently
stimulate T cell activation and expansion through the
endogenous TCR, via immunization with a potent im-
munogen, while antitumor reactivity could be carried
out by the genetically engineered antitumor receptor.
CAR genes have been used to generate dual-specific
cells from T cells with endogenous TCR specificity for
EBV (Rossig et al., 2002), CMV (Heemskerk et al., 2004),
or allogeneic antigen (Kershaw et al., 2002b). Dual-spe-
cific T cells have been demonstrated to respond
through both endogenous TCR and CAR in vitro and
to proliferate and inhibit tumors in vivo after adoptive
transfer and immunization (Kershaw et al., 2002b).
The therapeutic application of these T cells would in-
volve their transfer into cancer patients followed by im-
munization with the powerful immunogen. This ap-
proach simultaneously circumvents potential impasses
at several crucial immune response steps by assigning
responsibility for T cell activation and expansion to a
highly responsive yet separate receptor from that en-
coding tumor reactivity.
Therefore genetic modification strategies can be
used to initiate and amplify an immune response to tu-
mors, but this may prove fruitless if T cells are unable
Immunity
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aT cell migration to tumors is therefore an important goal
of immunotherapists. m
b
iStage 4: Migration and Recruitment of Immune Cells
bThe secretion of chemokines by cells within challenged
etissues normally creates a chemoattractant gradient
cthat leads to recruitment of activated T cells to the site
t(Figure 1, stage 4). A range of innate immune system
Tcells including macrophages, neutrophils, dendritic
mcells, and NK cells may also be attracted to the site,
amplifying the immune response, and participating in
gthe resolution of the threat.
gHowever, tumor tissue may not produce appropriate
cchemokines, and the lack of efficient trafficking of spe-
Icific T cells to tumor locations is one factor that may
crestrict robust antitumor responses. Indeed, induction
Iof antitumor immune responses has been shown to
ecorrelate with T cell infiltration at the tumor site, and
btransfer of tumor-reactive T cells has been shown to be
rmore effective at eliminating tumors when administered
cwithin the immediate proximity of tumors in selected
canimal models (Pinthus et al., 2003). If localization of
fleukocytes can be reproducibly enhanced to a range of
aadvanced physiologically relevant tumors, better tumor
icontrol may be achieved.
cExpression of specific chemokines at the tumor site
vis one approach that may enable specific T cells bear-
ting the relevant ligands to be better directed toward
jtumors. Genetic modification of tumors to express
nchemokines such as lymphotactin (XCL1) has been
mshown to attract CD4+ and CD8+ antigen-specific T
(cells in vitro and to eradicate well-established subcuta-
neous tumors in vivo when used in combination with
sadoptive T cell transfer (Huang et al., 2002a). This was
ein comparison to mice treated with either the chemo-
(kine gene or T cells alone. Similar reports of T cell in-
sfiltration and tumor regression have been observed in
pother mouse studies where tumor cells were modified
(with chemokine genes, including CCL27 (Gao et al.,
c2003a), macrophage-derived chemokine gene (CCL22)
i(Guo et al., 2002), IFN-γ-inducible protein 10 (IP-10,
sCXCL10) (Huang et al., 2002b), and macrophage inflam-
ematory protein 3α (MIP-3α, CCL20) (Fushimi et al.,
m2000). Combinations of chemokine genes have also
cbeen demonstrated to stimulate proliferation of CD8+ T
cells and to chemoattract T cells more efficiently than
aeither chemokine alone. In a mouse model, intratumoral
tinjection of both XCL1 and CXCL10 chemokine genes,
htogether with adoptive T cell transfer, not only signifi-
mcantly enhanced T cell infiltration of tumors when com-
tpared to either gene alone, but the majority of treated
lmice were tumor-free (Huang and Xiang, 2004).
tAnother molecule of interest is the TNF superfamily
tligand LIGHT, which regulates T cell immune responses
tby signaling through the herpesvirus entry mediator
(HVEM) and the lymphotoxin-β receptor. Gene transfer
bof LIGHT into tumor cells has been shown to induce
nmassive infiltration of T cells that correlated with in-
bcreased expression of chemokines and adhesion mole-
wcules and eradication of established tumors (Yu et al.,
i2004).
As an alternative to tumor cell modification, DCs podified to secrete T cell-attracting chemokines may
lso find application in tumor immunotherapy. Intratu-
oral injection of DCs expressing CCL21/SLC has
een demonstrated to enhance the antitumor response
n mice when compared to treatments involving fibro-
lasts expressing CCL21 or DCs lacking CCL21 (Yang
t al., 2004). Increased recruitment of T cells was asso-
iated with the antitumor response. It was thought that
ransferred DCs persisting at the injection site attracted
cells that could then be stimulated in situ within tu-
ors and exert subsequent effector function locally.
As further examples of how combinations of strate-
ies can be used to enhance the antitumor response,
enes encoding lymphocyte-attracting chemokines
an be successfully combined with cytokine genes.
ntratumoral coinjection of two adenoviruses, one en-
oding the chemokine CXCL10 and another encoding
L-12, resulted in marked antitumor synergy. This gen-
rated a powerful tumor-specific T cell response with
oth CD4+ and CD8+ T cells present in the infiltrate of
egressing tumors (Narvaiza et al., 2000). Similarly,
oinjection of adenovirus vectors coding for CXC
hemokines and IL-12 into murine adenocarcinoma or
ibrosarcoma resulted in considerable tumor regression
nd increased survival of injected mice. However, T cell
nfiltration was not specifically demonstrated in this
ase (Palmer et al., 2001). In another study, T cell acti-
ation and infiltration into tumors in association with a
ype 1 immune response was demonstrated upon coin-
ection of both IP-10 and IL-18 genes at the same tumor
odule, causing complete regression of established tu-
ors in 8 of 10 mice, compared with either gene alone
Liu et al., 2002).
An alternate approach to modifying cells at the tumor
ite is to engineer T cells with receptors for chemokines
xpressed on tumors. Growth-regulated oncogene-α
Gro-α, CXCL1) was demonstrated to be secreted by
everal human tumor cell lines, but T cells did not ex-
ress the appropriate chemokine receptor, CXCR2
Kershaw et al., 2002a). In subsequent experiments, T
ells were retrovirally transduced with a vector encod-
ng CXCR2, and a chemotactic response was demon-
trated in vitro toward tumor-derived CXCL1 (Kershaw
t al., 2002a). Redirecting T cell migration toward tu-
or-secreted chemokines may enhance effector cell lo-
alization at the tumor site.
The use of chemokine and cytokine genes to both
ctivate and attract tumor-specific T cells may be fur-
her enhanced by the inclusion of genes encoding ad-
esion molecules, such as the intercellular adhesion
olecule-1 (ICAM-1), which has been shown to facili-
ate cellular migration into inflammatory sites and cyto-
ytic interaction with tumors (Sartor et al., 1995) Aiding
hese types of interactions between lymphocytes and
umors may result in more efficient tumor targeting and
hus prove beneficial to achieving tumor eradication.
Although localization of immune cells to tumors can
e genetically augmented, simply getting to the site is
ot sufficient to eradicate tumors. Immune cells must
e able to exert robust effector and auxiliary functions
ithin tumors, and enhanced action might be expected
f these functions can be maintained for prolonged
eriods of time.
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Antitumor Functions
Approaches to enhance persistence of T cells may in-
volve genetic modification of tumors with costimulatory
molecules such as CD80 and CD86, which deliver sur-
vival signals to T cells (see “Stage 3” text above). Direct
modification of T cells with receptors such as CD28,
CD134, and CD137, mentioned previously in Stage 3
can also enhance T cell persistence. Increased T cell
survival through the use of costimulatory genes likely
results from inhibition of apoptosis, but direct manipu-
lation of genes important in apoptosis of T cells is an-
other method of inhibiting the early demise of specific
T cells. Indeed, genes encoding overexpression of the
antiapoptotic molecules Bcl-2 or Bcl-X(L) have been
demonstrated to enhance the survival of T cells (Eaton
et al., 2002; Lin and Wang, 2002).
Along with the importance of long-term persistence
of tumor-specific T cells is the ability of these cells to
execute potent antitumor effects. Potential mecha-
nisms to enhance the cytolytic activity of lymphocytes
include gene transfer into tumor of ligands for apopto-
sis-inducing cytokines such as lymphotoxin β (Brown-
ing et al., 1996) and tumor necrosis factor (TNF) (Gnant
et al., 1999). Tumor regression and growth inhibition has
been demonstrated upon subsequent systemic admin-
istration of the relevant T cell-derived cytokines. It is
hoped that by genetically increasing the susceptibility
of tumors with receptors to apoptosis-inducing cyto-
kines they may become more sensitive to tumor-spe-
cific T cells or doses of these cytotoxic agents.
Other approaches utilizing members of the TNF su-
perfamily include TNF-related apoptosis-inducing li-
gand (TRAIL), which is thought to be nontoxic to normal
cells while killing a broad range of tumor cells. Gene
transfer of TRAIL into tumor cells has induced apopto-
sis and blocked growth of TRAIL receptor-expressing
human tumor cell lines derived from colorectal, lung,
prostate, and liver cancer in vitro, and local administra-
tion of viral vectors expressing the TRAIL gene has
been demonstrated to be useful in treating established
tumors in animals (Jacob et al., 2004; Mohr et al., 2004).
However, expression of the TRAIL gene is likely to re-
quire regulation by a tumor-specific promoter to pre-
vent potential liver toxicity demonstrated in some ex-
periments (Armeanu et al., 2003; Lin et al., 2002).
Many of these attempts to enhance tumor suscep-
tibility to immune eradication are reliant on intratumoral
gene delivery, which can induce a strong and specific
immune response in murine studies. However, this ap-
proach would likely be more limited in humans to easily
accessible tumors. In addition, as with many ap-
proaches advocating genetic modification of tumors in
situ, success may be dependent on improvements in
vector technology that enable modification of the ma-
jority of tumor cells. An alternative to this is to transfer
genes enabling increased cytotoxic functions into T
cells. This was shown to be possible in experiments
where tumor-reactive lymphocytes were transduced
with the gene for TNF in an attempt to deliver high con-
centrations of TNF to the tumor site without dose-limit-
ing systemic toxicity (Hwu et al., 1993). However, TNF
production was low and not durable, and future thera-
peutic applications of this may depend on the develop-ment of vectors enabling higher production of this cy-
tokine in an inducible manner.
Another important factor to consider is the secretion
of immunomodulatory cytokines by tumor cells and
surrounding stromal cells. This can have dramatic ef-
fects on the persistence of tumor-reactive T cells and
the maintenance of their activity within tumors. For ex-
ample, a T cell inhibitory cytokine, transforming growth
factor-β (TGF-β), has been demonstrated to be se-
creted by a variety of tumors, resulting in inhibition of
antitumor immunity. Strategies aimed at circumventing
the effects of TGF-β include genetic modification of tu-
mor-reactive T cells with a dominant-negative TGF-β
receptor. T cells modified in this manner were found
to possess enhanced antitumor function in vitro when
compared to unmodified T cells (Bollard et al., 2002).
This tumor-mediated immunosuppression may in part
explain previous failures of adoptively transferred T
cells to mediate antitumor effects. Bestowing resis-
tance to these effects on T cells by gene transfer may
prove an important strategy to allow T cells to better
defend themselves in their confrontation with tumors.
Technical and Safety Issues
and Concluding Remarks
In this review, we have covered a wide range of genetic
modification strategies that are aimed at inducing an
immune response against tumors. However, it is impor-
tant to consider these genetic strategies in relation to
nongenetic approaches to immunotherapy where the
major areas of investigation include vaccines, monoclo-
nal antibodies, cytokines and adoptive cell transfer.
Vaccines can take one of several forms, including tu-
mor-associated proteins or peptides either alone, with
adjuvant, or pulsed onto dendritic cells. The most
promising results with vaccines have been observed
against melanoma and viral-induced malignancies,
which have demonstrated that the immune system can
be manipulated to produce dramatic antitumor re-
sponses against some malignancies (Rosenberg, 2001).
However, although precursor frequencies of tumor-spe-
cific T cells can be increased after vaccination, com-
plete durable responses are rare, and vaccines fre-
quently fail to prevent tumor growth (Rosenberg et al.,
2004). A large field of study focuses on loading den-
dritic cells (DCs) with tumor antigens in an effort to bet-
ter stimulate endogenous T cell responses. Tumor anti-
gen peptide- or protein-pulsed DCs can be effective at
raising antitumor responses in mice, and multiple clin-
ical trials have evaluated the safety and efficacy of
cancer vaccines based on tumor antigen-pulsed DCs
(Engleman, 2003). However, this approach has disad-
vantages associated with the short duration of antigen-
MHC complexes and the requirement for matching
defined peptides with MHC haplotypes. In contrast,
modification of DCs with genes encoding tumor antigen
can result in prolonged presentation of multiple epi-
topes by various class I and class II MHCs, with the
ability to activate antigen-specific T cells. Nevertheless,
vaccines are appealing from the point of view of ease
of administration, and future advances in our under-
standing of immune activation and maintenance may
lead to more effective vaccination methods.
Immunity
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Clinical
Immune Stage Gene Cell Reference Comments Trial
Initiation Antigen DCs (Ribas et al., 2002) Induction of tumor-specific T cells and yes
enhanced survival of tumor-bearing mice
CD40L DCs (Kikuchi et al., 2000) Regression of day 8 s.c. murine tumors, no
survival advantage, and protection
against subsequent challenge
CD40L Tumor (Kikuchi and Crystal, 1999) Sustained regression of established s.c. yes
tumors and protection against
subsequent challenge in mice
GM-CSF Tumor (Dranoff et al., 1993; Enhanced survival of tumor-bearing mice yes
Levitsky et al., 1996)
Flt3-L Tumor (Mach et al., 2000) Prevention of tumor growth in mice no
IL-1β Tumor (Bjorkdahl et al., 2000; Differential effects in mice depending on no
Saijo et al., 2002) use of active or inactive forms
IL-12 DCs (Nishioka et al., 1999) Regression of established (day 7) weakly yes
immunogenic tumors in mice
IL-18 DCs (Tatsumi et al., 2002) Inhibition of day 7 s.c. tumors in mice no
IL-12 + IL-18 DCs (Tatsumi et al., 2003) Regression of day 7 s.c. tumors and no
increased survival
Antigen Stem cells (Cui et al., 2003) Decreased tumour growth and increased no
survival in treated mice
Antiapoptotic DCs (Kim et al., 2003) Increased DC survival in vitro and no
molecules enhanced T cell generation and tumor
inhibition in mice
Specific T cells TCR T cells (Chamoto et al., 2004) Eradication of small A20-OVA tumors in yes
mice
TCR Progenitors (Yang et al., 2002) Prolonged production of specific T cells no
CARs T cells (Sadelain et al., 2003) Regression of early or deseminated tumors yes
in mice
Expansion CARs + CD28 T cells (Finney et al., 2004; Haynes T cell proliferation in vitro and eradication no
et al., 2002b) of 5 day lung metastases in mice
CD80, CD86 Tumor (Li et al., 1994; Townsend Eradication 8 day s.c. tumors yes
and Allison, 1993)
OX40, 4-1BB Tumor (Andarini et al., 2004) Tumor inhibition and increased tumor- no
specific T cells
RANK/RANK-L DCs (Wiethe et al., 2003) Enhanced T cell response in mice no
IL-2, IL-7, IL-4 Tumor (Bowman et al., 1998; Hock Leukocyte infiltration, reduced yes
et al., 1993; Levitsky et al., tumorigenicity, enhanced survival in mice
1996)
CAR Dual-specific (Kershaw et al., 2002b) Tumor inhibition and T cell expansion yes
T cells in mice
Leukocyte Chemokine Tumor (Gao et al., 2003a) Lymphocyte infiltrate and reduced no
recruitment tumorigenicity
LIGHT Tumor (Yu et al., 2004) Massive leukocyte infiltrate and eradication no
of established allogeneic tumors
Chemokine DCs (Yang et al., 2004) Eradication of 5-day s.c. tumors in 60% no
of mice
Chemokine T cells (Kershaw et al., 2002a) T cell migration in vitro no
receptor
ICAM-1 Tumor (Sartor et al., 1995) Reduced tumorigenicity no
Persistent and Bcl-2 T cells (Lin and Wang, 2002) Enhanced survival of T cells in vitro no
maintaining
activity
TNF-R Tumor (Gnant et al., 1999) Tumor inhibiton no
TRAIL Tumor (Lin et al., 2002) Tumor inhibition no
TNF T cells (Hwu et al., 1993) Constitutive expression by T cells in vitro no
Dominant – T cells (Bollard et al., 2002) T cell resistance to TGF-β-mediated no
ve TGFβ-R inhibition in vitro
Strategies are grouped according to the most relevant stage of the immune response involved. A diverse range of genes and target cell types
is employed to effectively stimulate an antitumor response. An appraisal of the relative capacity of each approach to impact on tumor
immunity can be obtained from the Comments column. References are representative of each area.Monoclonal antibodies, either alone or conjugated to p
odrugs or toxins, are gaining acceptance in the clinic
and can be useful against lymphoma or breast cancer f
t(von Mehren et al., 2003). Humanized antibody can be
produced in large amounts and easily administered toatients. However, issues such as low-level penetration
f tumor, poor ability to recruit appropriate effector
unction, and toxicity have resulted in limited applica-
ion and low response rates for most malignancies.
Similarly, cytokines including interferons and IL-2 can
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ical effectiveness is largely restricted to melanoma, re-
nal cell carcinoma, and some hematologic malignan-
cies, where low-to-moderate response rates have been
observed (Smyth et al., 2004). Although large amounts
of recombinant cytokines can be produced and easily
administered, severe toxicity is often observed with this
type of therapy that activates immune mechanisms in
a largely nonspecific manner.
Adoptive immunotherapy, involving the ex vivo gen-
eration of large numbers of activated tumor-reactive
lymphocytes, can have dramatic effects on established
tumors particularly when used in combination with IL-2
(Rosenberg, 2001). However, the approach is cumber-
some at present and again responses are limited to
only a proportion of patients with melanoma.
Thus, the above nongenetic approaches can have
advantages in certain situations, and some remarkable
responses have been documented. However, the ma-
jority of malignancies do not respond to current immu-
notherapies, and issues regarding toxicity are concern-
ing. Clearly, there is a need for more precise therapies
that can enhance specific immune elements against a
broader range of cancers.
Elucidation of the many molecular and genetic
events underlying each of the key steps involved in a
successful immune response has led to the genetic
manipulation of many immune targets in attempts to
reinforce crucial components of the anti-tumor re-
sponse. Here, we have outlined many strategies utiliz-
ing genetic modification in attempts to boost the im-
mune system against cancer that are summarized in
Table 1. An estimate of the relative effectiveness of
each strategy can be gained from comparison of the
“best achieved to date” comments for each approach.
Some strategies have only progressed as far as demon-
strating function in vitro or tumor inhibition in simple
mouse models, whereas others have achieved tumor
eradication in mice and have progressed to clinical trial.
However, in the clinic, responses are infrequent and
rarely durable, and are limited to a minority of patients
with one of only a limited range of malignancies. The
studies detailed in this review suggest a need to com-
bine several approaches to enhance multiple aspects
of the immune response in order to generate robust
anti-tumor responses. For example, optimal therapy
may involve transfer of DCs transduced with genes en-
coding antigen, in combination with supplying autolo-
gous T cells modified to respond to antigen, along with
a vector for expression of appropriate chemokine in tu-
mor tissue.
At present, technological limitations render genetic
modification of DCs or T cells laborious and expensive.
However, improved approaches may lead to effective
in vivo gene transfer that enables stable gene expres-
sion. Similarly, genetic modification of tumor is limited
at present. Better targeted, more stable transgene ex-
pression in the majority of tumor cells may enhance
many of the approaches described above. Future im-
provements in vector design and specific targeting of
tumors may make this a reality.
A number of vector systems are available for investi-
gators to choose from that have a variety of advantages
and disadvantages (Kay et al., 2001). Nonviral vectorscan be used to deliver large gene “payloads” into cells
although their transfection efficiency is currently lim-
ited. Viral vectors include retrovirus that can produce
stable gene expression in cells and their progeny over
prolonged time periods due to genomic integration, but
active cell division is required for integration and the
amount of exogenous DNA is limited to approximately
8000 bp. Lentiviral vectors can be used to stably ex-
press genes in nondividing cells but, again, genes are
of limited size, and there are some misgivings about
these vectors due to their derivation from HIV. Vaccinia,
adenovirus and others can incorporate larger amounts
of DNA, but expression is transient and their applica-
tion in vivo may be limited by preexisting immunity.
Safety issues are also of concern with cutting edge
technology such as that embodied in the approaches
described in this review. Of particular concern is the
safety of viral vectors used for in vivo gene modifica-
tion. Recent incidents involving toxicity after gene
transfer through adenovirus highlight the need for a de-
tailed appraisal of risk for each area of application
(Somia and Verma, 2000). Also of concern is potential
malignant transformation of immune system cells fol-
lowing modification with vectors that can integrate into
the genome potentially disrupting oncogene regulation.
Recent examples of this in children receiving retrovirally
gene-modified stem cells to treat immune deficiency
highlight this concern (Hacein-Bey-Abina et al., 2003).
However, potential safety concerns need to be weighed
against potential benefit, and greater risk may be justi-
fied in patients with otherwise terminal disease.
Our knowledge of key cellular and molecular stages
in immunity together with our ability to gene modify
cells provides us with extraordinary opportunities to
circumvent impasses in immunity to tumors. Genes
may be used with greater precision and lower toxicity
than systemically applied adjuvants. Technological ad-
vances and an increasing understanding of immuno-
regulation may lead to combined immunomodulatory
gene approaches with enhanced effectiveness for the
treatment of cancer patients.
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